Our results suggest that IDH1 mutation status significantly impacts responsiveness to RNaseH2 inhibition, particularly in combination with TMZ, supporting a more personalized treatment approach to improve outcomes for glioma patients. The gene discussed is IDH1; the disease is central nervous system cancer.